Abstract
AbstractNew infections from the omicron variant of SARS-CoV-2 have been increasing dramatically in South Africa since first identification in November 2021. Despite increasing uptake of COVID-19 vaccine, there are concerns vaccine protection against omicron may be reduced compared to other variants. We sought to characterize a surrogate measure of vaccine efficacy in Gauteng, South Africa by leveraging real-time syndromic surveillance data. The University of Maryland Global COVID Trends and Impact Survey (UMD-CTIS) is an online, cross-sectional survey conducted among users sampled from the Facebook active user base. We derived three COVID-like illness (CLI) definitions (stringent, classic, and broad) using combinations of self-reported symptoms (present or not in the prior 24 hours) that broadly tracked with reported COVID-19 cases during June 18, 2021 - December 14, 2021 (inclusive of the delta wave and up-trend of the omicron wave). We used syndromic-surveillance-based CLI prevalence measures among the vaccinated (PV) and unvaccinated (PU) respondents to estimate V ECLIP = 1 - (PV /PU), a proxy for vaccine efficacy, during the delta (June 18-July 18, N= 9,387 surveys) and omicron (December 4-14, N= 2,389 surveys) wave periods. We assume no waning immunity, CLI prevalence approximates incident infection with each variant, and vaccinated and unvaccinated survey respondents in the two variant wave periods are exchangeable. The vaccine appears to have consistently lower V ECLIP against omicron, compared to delta, regardless of the CLI definition used. Stringent CLI (i.e. anosmia plus fever, cough and/or myalgias) yielded a delta V ECLIP = 0.85 [0.54, 0.95] higher than omicron V ECLIP = 0.62 [0.46, 0.72]. Classic CLI (cough plus anosmia, fever, and/or myalgias) gave lower estimates (delta V ECLIP = 0.76 [0.54, 0.87], omicron V ECLIP = 0.51 [0.42, 0.59]), but omicron was still lower than delta. We acknowledge the potential for measurement, confounding, and selection bias, as well as limitations for generalizability for these self-reported, syndromic surveillance-based V ECLIP measures. Thus V ECLIP as estimates of true, population-level vaccine efficacy should therefore be taken with caution. Nevertheless, these preliminary findings demonstrating declining V ECLIP raise concern for a true decline in vaccine efficacy versus waning immunity as a potential contributor to the omicron variant taking hold in Gauteng and elsewhere.
Publisher
Cold Spring Harbor Laboratory
Reference13 articles.
1. Ewen Callaway and Heidi Ledford . How bad is omicron? what scientists know so far. Nature News, 2021.
2. Bingrui Li , Xin Lu , Kathleen M. McAndrews , and Raghu Kalluri . Mutations in the spike rbd of sars-cov-2 omicron variant may increase infectivity without dramatically altering the efficacy of current multi-dosage vaccinations. bioRxiv, 2021.
3. Juliet R.C. Pulliam , Cari van Schalkwyk , Nevashan Govender , Anne von Gottberg , Cheryl Cohen , Michelle J. Groome , Jonathan Dushoff , Koleka Mlisana , and Harry Moultrie . Increased risk of sars-cov-2 reinfection associated with emergence of the omicron variant in south africa. medRxiv, 2021.
4. Discovery health, south africa’s largest private health insurance administrator, releases at-scale, real-world analysis of omicron outbreak based on 211,000 covid-19 test results in south africa, including collaboration with the south africa [press release]. Dec 2021.
5. Partnering with a global platform to inform research and public policy making;Survey Research Methods,2020